Biofocus

BioFocus DPI is a multinational company that aim to expand their partners' drug pipeline by accelerating the gene-to-candidate drug discovery process. They offer a biologically-focused discovery platform utilising target discovery in human prmary cells and chemogenomically-designed compound libraries.

Through full-length cDNA and shRNA constructs, BioFocus's genome-wide screening approach can be applied across a broad range of disease areas to rapidly identify and validate disease-modifying drug targets. Once a target has been selected, BioFocus's small-molecule libraries and natural product collections are excellent tools for hit generation. Their expertise in medicinal and computational chemistry as well as assay development and ADME-Tox capabilities further progress their partners' drug discovery programmes.

MerLion Pharmaceuticals

MerLion Pharmaceuticals Pte Ltd is a Singapore-based company, engaged in drug discovery from natural products. Its assets include one of the World's largest and most diverse natural product collections, proprietary purification technologies, high throughput screening (HTS) capabilities, proprietary IT database management systems and a highly experienced team.

MerLion focus on discrete R&D collaborations with pharmaceutical companies, biotechs and other research organisations possessing novel, validated targets in key therapeutic areas.

Sareum

Sareum Holdings plc is a structure-based drug discovery business headquartered in Cambridge, UK. Sareum Limited was formed in August 2003 to discover new drugs for the treatment of cancer and to provide a range of drug discovery services to the pharmaceutical industry.

Sareum's unique structure-based approach, innovative Template Screening platform and high-throughput medicinal chemistry platform aims to halve the time it takes to discover new drug candidates.